Biogen announced the European Commission, or EC, has granted marketing authorization under exceptional circumstances and maintained orphan designation for Qalsody for the treatment of adults with amyotrophic lateral sclerosis, or ALS, associated with a mutation in the superoxide dismutase 1 gene, or SOD1-ALS. Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease, or MND.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen reports Leqembi approved for treatment of Alzheimer’s in South Korea
- Biotech Alert: Searches spiking for these stocks today
- Biogen acquiring HI-Bio in increased immunology focus, says William Blair
- Biogen acquisition has positive read for IGM Biosciences, says RBC Capital
- Biogen deal for HI-Bio ‘makes sense,’ says Stifel